Please provide your email address to receive an email when new articles are posted on . 6.5% of patients with mild asthma had at least one acute exacerbation in the year after the index date.

Please provide your email address to receive an email when new articles are posted on . Patients with mild asthma are still at risk for severe exacerbations, which can impact their quality of life.

With the inclusion of the BATURA study, Airsupra has now demonstrated its effectiveness in reducing the risk of severe exacerbations across all severity levels of asthma vs albuterol. The Food and ...

Statins were linked to decreased risk for acute asthma exacerbations in mild asthma and had a significant protective effect in Black patients.

AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma.1 The BATURA Phase IIIb trial, which evaluated severe exacerbation ...

The BATURA trial ended early due to high efficacy data at pre-planned analysis. Topline results were announced from a phase 3b trial evaluating albuterol/budesonide metered dose inhaler in patients ...

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca’s inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated ...

In asthma, airway inflammation leads to bronchoconstriction (narrowing of airways), excess mucus production and swelling of ...

Adherence to daily maintenance therapy with inhaled glucocorticoids is notoriously poor among asthma patients with mild disease, with as many as four out of five failing to use the medications as ...

Congress Parliamentary Party chairperson Sonia Gandhi is “absolutely stable” and responding well to treatment after being ...